Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

First-Ever Spinal Surgical Hand-held Robot by Point Robotics MedTech to Make Its Worldwide Debut in the United States

TAIPEI, Sept. 28, 2022 /PRNewswire/ -- Point Robotics MedTech Inc. (Point Robotics), a rising star in the field of orthopedic surgery, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its minimally invasive surgical robot, POINT™ Kinguide Robotic-Assisted Surgical Sy...

2022-09-28 21:01 882

First-Ever Spinal Surgical Hand-held Robot by Point Robotics MedTech to Make Its Worldwide Debut in the United States

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world

* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...

2022-09-28 21:00 1806

ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442

First patient dosed with novel biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today anno...

2022-09-28 20:30 1181

Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows

VIPS PRO delivers powerful and efficient seeding technology and definitive proof of monoclonality for workflow productivity and confidence. NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ -- Advanced Instruments today announced the launch ofSolentim VIPS PRO, a high efficiency single cell seeder, at...

2022-09-28 20:05 1613

Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows

Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts

* Rising from last year's ranking, the company's united effort and dedication to integrating sustainable practices in all areas of its business drew recognition from EcoVadis, which provided high marks in responsible procurement and environmental management. * More than 100,000 companies from...

2022-09-28 19:00 1138

Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly. ABM Therapeutics Annou...

2022-09-28 18:31 1617

The 6th China (Shenzhen) Innovation & Entrepreneurship International Competition Eindhoven, Netherlands Division is Open for Registration

DIGITAL ACCESS TO THE WORLD CREATES A BETTER FUTURE EINDHOVEN, Netherlands, Sept. 28, 2022 /PRNewswire/ -- China （Shenzhen）Innovation and Entrepreneurship Competition, known as the "Olympics" of innovation and entrepreneurship circle, is here again! The sixth International competition was offici...

2022-09-28 17:55 1092

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment. Located in Solaris @ Tai Seng, this 1,300 square metres faci...

2022-09-28 17:34 4208

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S ("Contera") are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the...

2022-09-28 16:00 1414

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharmi...

2022-09-28 13:00 1863

ETANA HAS SECURED B ROUND FINANCING

JAKARTA, Indonesia, Sept. 28, 2022 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured B round of financing led by Yunfeng Capital and followed by HighLight Capital. This round of financing will be mainly used for further strengthening ...

2022-09-28 09:00 4079

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge ...

2022-09-28 06:50 1338

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

2022-09-27 21:40 1259

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

ATLANTA, Sept. 27, 2022 /PRNewswire/ -- CP Kelco, a global leader of nature-based ingredient solutions that is owned by J.M. Huber Corporation, and ExoPolymer, Inc., a biotechnology startup company focused on developing new-to-the-world, polysaccharide-based biopolymers, are excited to announce a ...

2022-09-27 21:00 1292

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

Metabolon Expands Data Access Strategy to Include Health for Life in Singapore (HELIOS) Study

Metabolon to collaborate with NTU Singapore's medical school to identify biomarkers for the prevention, diagnosis, and treatment of disease. MORRISVILLE, N.C., Sept. 27, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of res...

2022-09-27 19:57 1478

Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics

The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA delivery technology and expertise in developing RNAi therapeutics SAN FRANCISCO, Calif. and HANGZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Sciwin...

2022-09-27 08:00 1881

First Patient Enrolled in ProstACT TARGET Study

MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...

2022-09-27 05:00 1646

Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies

NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, h...

2022-09-26 21:00 1520

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...

2022-09-26 20:00 2056

PharmAbcine to Participate in BIO-Europe 2022

DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place ...

2022-09-26 20:00 1182

1 ... 109 110 111112113 114 115 ... 279